glioblastoma multiforme

Abysmal survival rates for patients with glioblastoma multiforme

Only few treatment options exist for glioblastoma multiforme

Glioblastoma multiforme (GBM) is the most common and aggressive primary CNS cancer with a median survival of just 15 months. The incidence of GBM is 22,000 in the US and Europe combined. GBM is a difficult disease to treat and conventional treatment options have demonstrated limited responses. The survival of patients suffering from GBM has not improved significantly in the past three decades. 


Standard therapy does not improve significantly survival rates

The current standard treatment consists of maximal safe resection, followed by radiation therapy and then maintenance chemotherapy.

Myc overexpression is a new promising drug target for glioblastoma multiforme

Myc activity is frequently altered in GBMs (over half of cases).